Wednesday, June 15, 2022

News from #ASCO22 - Part 6 News that Caught My Eye in Tweets

Palliative Care

Using Claims-based Data 


Sarcoma research

 Clinical trials

Cascade Testing and ovarian cancer

Rare cancer treatments


Thanks for joining me as I reviewed ASCO research. I hope to see you at ASCO next year. 


Every Day is a Blessing!

Tuesday, June 14, 2022

News from #ASCO22 Part 5 - Case Studies of Endometrial Cancer

This session was a case based discussion titled Controversies and Considerations in Adjuvant Advanced Endoemterial Cancer. 

Cases were presented and questions asked of the panel which included a patient advocate, @AdrienneEcana.

Tomorrow catch my last post from ASCO. It included varied Tweets of studies from the meeting that were not necessarily a part of the sessions I viewed.



Every Day is a Blessing! 

Monday, June 13, 2022

News from #ASCO22 Part 4- Gynecologic Cancer Poster discussion session

This post will cover the Gynecologic Cancer Poster discussion session at #ASCO22 held on Saturday June 5,2022 . I recently watched this on demand.Most of the posters discussed dealt with ovarian cancer.

1)Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study.   5512

 Mirvetuximab soravtansine is an antibody drug conjugate 

MIRV is the first biomarker-directed therapy demonstrating anti-tumor activity in pts with FRα high Platinum-resistant OC.

"MIRV is the first biomarker directed therapy showing anti-tumor activity in patients with Platinum resistant OC". Link to abstract


 2) Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial. 5513

This study also used an antibody drug conjugate.

"MORAb-202 is an antibody-drug conjugate consisting of farletuzumab (an antibody that binds to folate receptor alpha [FRα]) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin-B–cleavable linker). "

This was a Japanese expansion study and"efficacy was observed irrespective of FRα-expression levels. 


slide from distillation presentation -Maroney

3)A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150. 5514

"Anetumab ravtansine (AR) is a fully-human antibody directed at the mesothelin antigen, conjugated to a tubulin polymerization inhibitor". Study was of combination AR/bevacizumab (ARB) versus weekly paclitaxel/bevacizumab (PB). 

 PB had better outcome than weekly ARB leading to the study termination.

Second Group of Posters: Targeted Therapies


4) IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification. 5515 

Adavosertib is a Wee1 inhibitor 

53%Overall response rate , Clinical benefit 61%, 53% had dose reductions. 
Progression Free survival not yet available.   
5) Adavosertib in combination with carboplatin in advanced TP53-mutated platinum-resistant ovarian cancer.   5516
38% overall response rate and  76%had dose delays

"Adavosertib 225 mg BID for 2.5 days and carboplatin AUC 5 in a 21-day cycle could be safely combined and shows promising anti-tumor efficacy in patients with platinum resistant ovarian cancer. "
6)Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO) 5517
"LIO-1 is assessing the oral antiangiogenic, multikinase inhibitor lucitanib in combination with the programmed cell death receptor 1 (PD-1) inhibitor nivolumab"
22% overall response rate and 46% treatment interruptions. 
Third Group of Posters - Maximize remission
7) Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study. 5518   Real world results follow the SOLO-1 results.  Providers asked to provide information on their patients. 36% of the population were on maintenance only 26% received PARP.                               
Slide from Norquist discussion

"There was prolonged benefit of 1L olaparib in newly diagnosed pts with BRCAm AOC in terms of lower likelihood of progression."
8 Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.  5519 

"In final OS analyses, maintenance olaparib capsules showed consistent clinical activity in BRCAm and sBRCAm PSROC paitents. Exploratory analyses suggest similar activity in non-BRCA HRRm pts."  

9)Role of cytoreductive surgery for the second ovarian cancer relapse in patients previously treated with chemotherapy alone at first relapse: A subanalysis of the DESKTOP III trial. 5520  

"Cytoreductive surgery for subsequent ovarian cancer relapse appears feasible and with low mortality in selected patients who received non-surgical treatment at 1st relapse despite a positive AGO-score." The AGO score is a predictor for which ovarian cancer patients can be operated on with a first recurrence.      

 Rare Gyn Malignancies

10)Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)  5521 

ONA-XR is a type I full progesterone antagonist that inhibits progesterone-mediated progesterone receptor activation and stabilizes progesterone receptor association with corepressors. 

 "ONA-XR exhibited a 12-month PFS rate of 20.1% and a CBR of 35.7% in patients with GCT ."                                      

11)A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.  5522


"Neoadjuvant treatment with fulvestrant and abemaciclib was tolerable and demonstrated unprecedented response and CGR rates in this pilot study."


12) Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer.  5523 



"Our web-based online interactive tool can help with identifying areas with high need of intervention, and inform how access, prevention and new or emerging therapies may potentially change the distribution of r/mCC disease burden"




My last ASCO Annual Meeting post will be the Clinical Science Symposium on Molecular Based Treatment of  Endometrial cancer.






































































































































































































































































































Every Day is a Blessing!